Evaluation of the Safety and Tolerability of a Timolol-Releasing Intraocular Implant in Patients with Primary Open-Angle Glaucoma

The primary objective of this study is to evaluate the **safety** and **tolerability** of a timolol releasing intraocular implant in subjects with **primary open-angle glaucoma**. This is clinically relevant as it aims to assess a potential new treatment option for managing intraocular pressure in patients with this common form of glaucoma, which can lead to vision loss if not effectively controlled. No secondary objectives are provided.

The clinical trial focuses on participants diagnosed with **glaucoma**. The study population includes both male and female subjects, with an age range spanning from 18 to 64 years. Participants are generally in good health, excluding the presence of the specified medical condition. The trial does not involve a vulnerable population. The sponsor has not provided information regarding the total number of participants. Selection criteria for the trial population have not been disclosed, and there are no specific lifestyle considerations such as diet or physical activity mentioned. Key inclusion or exclusion criteria have not been specified by the sponsor.

The clinical trial is designed to evaluate the **safety** and tolerability of a timolol-releasing intraocular implant in subjects diagnosed with **primary open-angle glaucoma**. This study is structured as a Phase 1 trial, which is typically the initial phase in clinical research focusing on assessing the safety profile of a new intervention. The trial is expected to commence recruitment on March 1, 2024, and is projected to conclude by May 1, 2027. The trial will employ a randomized, double-blind, controlled design to ensure the reliability and validity of the results, minimizing bias and allowing for a robust comparison between the intervention and control groups.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. This initial visit will involve a comprehensive assessment to ensure that participants meet the necessary inclusion criteria and do not fall under any exclusion criteria. Following successful screening, participants will be randomized into either the treatment or control group. Throughout the trial, participants will attend regular follow-up visits, which will be scheduled at predetermined intervals to monitor their health status, assess the implant's effects, and collect data on any adverse events. These visits are crucial for evaluating the ongoing safety and tolerability of the implant.

The end-of-study visit will mark the conclusion of the participant's involvement in the trial. During this visit, a final assessment will be conducted to gather comprehensive data on the participant's condition and any long-term effects of the treatment. The expected length of participant involvement will vary depending on the individual's response to the treatment and adherence to the study protocol. Conditions that may lead to early termination from the study include the occurrence of significant adverse events, non-compliance with study procedures, or withdrawal of consent by the participant. The trial's design and procedures are meticulously planned to ensure the collection of high-quality data while prioritizing participant safety and well-being.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, or frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these treatments can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be elaborated upon in this context.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an early stage of clinical research primarily focused on safety and dosage. The estimated recruitment start date is March 1, 2024, with an anticipated end date of May 1, 2027. Although specific efficacy parameters such as primary or secondary endpoints are not detailed, typical Phase 1 trials often involve preliminary assessments of efficacy alongside safety evaluations. The trial will likely employ standardized methods for measuring and collecting data, which may include validated scales, laboratory tests, or patient-reported outcomes, depending on the investigational product and the condition being studied. The schedule for these assessments will be aligned with the trial's protocol, ensuring systematic data collection at predefined timepoints throughout the study duration. The analysis of efficacy data will be conducted using appropriate statistical methods to determine the investigational product's potential therapeutic effects.